Dr. You received his M.D. from the West China University of Medical Sciences in 1989. He conducted his doctoral studies on the chemotherapy of gynecologic cancer under the tutelage of Dr. Zeyi Cao at the same institution, obtaining his Ph.D. in 1994. From 1994 to 1998, Dr. You was a postdoctoral fellow and then a faculty member at the Beijing Medical University, working on the molecular biology of gynecologic cancer. In 1998, Dr. You joined the University of Freiburg, Freiburg, Germany, as a research scientist to investigate adenovirus-mediated cancer gene therapy. In 2000, he moved to the University of Michigan, Ann Arbor, as a research fellow focusing on molecular signaling and apoptosis in cancer. In 2003, Dr. You joined the faculty of the University of California Davis as an adjunct instructor and then an adjunct assistant professor in the Department of Orthopaedic Surgery, working on the interleukin-17 receptor-like molecule (IL-17RL or IL-17RC) in prostate cancer. In 2008, Dr. You joined the faculty of the Tulane University Health Sciences Center as an assistant professor in the Department of Structural and Cellular Biology. In 2014, Dr. You was promoted to associate professor with tenure. Dr. You's cancer research interest is to understand the role of inflammation in cancer initiation, promotion, and progression. His target molecule in inflammation is interleukin-17 (IL-17). IL-17 is a key cytokine in many inflammatory and autoimmune diseases. His lab is using in-vitro and in-vivo (transgenic and knockout mice) approaches to determine the role of IL-17 signaling in initiation, promotion, and progression of prostate cancer. The long-term goals of these studies are to identify the molecular mechanisms of IL-17 signaling pathways, to develop new methods targeting IL-17 signaling, and to apply these methods in the prevention and treatment of prostate cancer.
Dr. You is interested in inflammation and prostate cancer, focusing oninterleukin-17-mediated inflammation in prostate cancer development and progression. His lab has used a variety of mouse models, e.g., human xenograft(subcutaneous, orthotopic, and intratibial injections) mice, TRAMP mice, and Pten-conditional knockout mice, to investigate IL-17’s roles in the development of hormone-naïve and castration-resistant prostate cancer. In recent years, Dr. You’s lab has focused on obesity and prostate cancer. His lab has demonstrated that insulin/IGF1 signaling crosstalks with IL-17 signaling through GSK3.
Teaching Interests:
Gross Anatomy (Lecture on Pelvis and Perineum; Laboratory Director for Block II);
Molecular Medicine (T Cell Lineages);
Aging Studies Proseminar (Osteoarthritis and Other Cartilage Changes during Aging);
Cancer Biology and Pathology (Tumor Immunology and Immunotherapy);
Anatomy Research Seminars II (Course Director).
Other Academic Affiliations:
Adjunct Associate Professor in Department of Orthopaedic Surgery
Program Member of Tulane Cancer Center, Louisiana Cancer Research Consortium
Faculty Member of Tulane Center for Aging
Faculty Member of Tulane Center for Stem Cell Research and Regenerative Medicine
Interleukin-17 in Prostate Cancer. A major focus of our research program is to understand the role of inflammation in cancer initiation, promotion, and progression. Our target molecule in inflammation is interleukin-17 (IL-17). IL-17 is a key cytokine in many inflammatory and autoimmune diseases. We are using in-vitro and in-vivo (transgenic and knockout mice) approaches to determine the role of IL-17 signaling in initiation, promotion, and progression of prostate cancer. The long-term goals of these studies are to identify the molecular mechanisms of IL-17 signaling pathways, to develop new methods targeting IL-17 signaling, and to apply these methods in prevention and treatment of prostate cancer.
Doublecortin in Articular Joint Development. This research program is to understand the role of doublecortin (DCX) in development of articular joint. DCX was originally identified in migrating and differentiating neurons by other investigators. We were the first group to identify DCX in articular chondrocytes. Our current studies are to identify the molecular mechanisms of DCX’s function and to determine the role of DCX in differentiation of stem cells into articular chondrocytes. The long-term goals are to design new approaches in tissue engineering and regeneration of articular joint by manipulating DCX expression.
You, Z., Shi,X.B., DuRaine, G., Haudenschild, D., Tepper, C.G., Lo, S.H., Gandour-Edwards,R., deVere White, R.W., and Reddi, A.H. Interleukin-17 Receptor-like gene is anovel antiapoptotic gene highly expressed in androgen independentprostate cancer. Cancer Res 66 (1):175-83.
QiuyangZhang, Sen Liu, Dongxia Ge, Qingsong Zhang, Yun Xue, Zhenggang Xiong, Asim B.Abdel−Mageed, Leann Myers, Steven M. Hill, Brian G. Rowan, Oliver Sartor,Jonathan Melamed, Zhenbang Chen, and Zongbing You. Interleulin-17Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models.Cancer Research, 72 (10):2589-99, 2012– featured on the cover of the May15, 2012 issue of Cancer Res.
QiuyangZhang, Sen Liu, Keshab R. Parajuli, Zhongfu Mo, Jing Liu, Zhiquan Chen, ShijieYang, Alun R. Wang, Leann Myers, and Zongbing You. Interleukin-17promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.Oncogene 36:687-699, 2017.
Zongbing You, Ying Dong, Xiangtian Kong, Laurel A. Beckett, Regina Gandour-Edwards, and Jonathan Melamed. Midkine is a NF-κB-inducible gene that supports prostate cancer cell survival. BMC Medical Genomics 2008, 1:6.
Dongxia Ge, Zongbing You. Expression of interleukin-17RC protein in normal human tissues.International Archives of Medicine 2008, 1:19.
View Pubmed listing of Dr. You's research publications
Junliang Ma, Lunxu Liu, Guowei Che, Nanbin Yu, Fuqiang Dai, and Zongbing You. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112.
Fuqiang Dai, Lunxu Liu, Guowei Che, Nanbin Yu, Qiang Pu, Shangfu Zhang, Junliang Ma, Lin Ma and Zongbing You. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 10 (2010) 220.
Q. Zhang, A.D. Cigan, L. Marrero, C. Lopreore, S. Liu, D. Ge, F.H. Savoie, and Z. You, Expression of doublecortin reveals articular chondrocyte lineage in mouse embryonic limbs. Genesis 49 (2011) 75-82. PMID: 21162077.
T. Lai, K. Wang, Q. Hou, J. Zhang, J. Yuan, L. Yuan, Z. You*, and M. Xi*, Interleukin 17 Induces Up-Regulation of Chemokine and Cytokine Expression Via Activation of the Nuclear Factor kappaB and Extracellular Signal-Regulated Kinase 1/2 Pathways in Gynecologic Cancer Cell Lines. Int J Gynecol Cancer (2011). 21: 1533-9.
Dongxia Ge, Allen C. Gao, Qiuyang Zhang, Sen Liu, Yun Xue, and Zongbing You. LNCaP Prostate Cancer Cells with Autocrine Interleukin-6 Expression Are Resistant to IL-6-induced Neuroendocrine Differentiation due to Increased Expression of Suppressors of Cytokine Signaling. The Prostate, 2012 Sep 1;72(12):1306-16.
Qiuyang Zhang, Sen Liu, Dongxia Ge, Qingsong Zhang, Yun Xue, Zhenggang Xiong, Asim B. Abdel−Mageed, Leann Myers, Steven M. Hill, Brian G. Rowan, Oliver Sartor, Jonathan Melamed, Zhenbang Chen, and Zongbing You. Interleulin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models. Cancer Research, 72 (10):2589-99, 2012– featured on the cover of the May 15, 2012 issue of Cancer Res.
Zongbing You, Dongxia Ge, Sen Liu, Qiuyang Zhang, Alexander D. Borowsky, and Jonathan Melamed. Interleukin-17 Induces Expression of Chemokines and Cytokines in Prostatic Epithelial Cells but Does Not Stimulate Cell Growth In Vitro. International Journal of Medical and Biological Frontiers. 2012, 18 (8): 629-644.
Lunxu Liu, Dongxia Ge, Lin Ma, Jiandong Mei, Sen Liu, Qiuyang Zhang, Fuqiang Ren, Hu Liao, Qiang Pu, Tao Wang, and Zongbing You. Interleulin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage-dominant Microenvironment in Lung Cancer. J Thoracic Oncology, 2012 Jul; 7(7):1091-1100.
Qingli Li, Mark J. Lambrechts, Qiuyang Zhang, Sen Liu, Dongxia Ge, Rutie Yin, Mingrong Xi, Zongbing You.Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis. Drug Design, Development and Therapy, July 24, 2013, 7: 635-643.
MyNCBI link: Complete Listof 94 Published Papers in MyBibliography:
https://www.ncbi.nlm.nih.gov/myncbi/zongbing.you.1/bibliography/public/
Keywords/Tags: animal models of prostate cancer,cytokines and chemokines, IL-17 and IL-17 receptors, inflammation, tumor immunemicroenvironment, and cancer immunology.
View Pubmed listing of Dr. You's research publications
